FEATURED

Preexisting Immunity to CRISPR-Cas9

Evidence is building to show that most people have preexisting immunity to CRISPR-based therapies. In cancer, however, it's unclear how much that matters.

Cancer Recurrence: A Valid Survivor Fear

Researchers are learning that roughly half of survivors live with a moderate to high degree of fear of recurrence, and teaching techniques to better cope with uncertainty is one way to help.

Lower-Dose, Shorter-Duration Chemotherapy

Lower doses and shorter treatment regimens have the potential to reduce both physical and financial toxicity for patients.

Ask the Experts: NSCLC

Cancer Therapy Advisor asked 2 experts to weigh in on recommended treatment modalities for patients with non-small cell lung cancer.

Ask the Experts: STS Clinical Insights

Cancer Therapy Advisor asked 2 experts to weigh in on the latest clinical insights into soft tissue sarcoma.

Ask the Experts: Waldenström Macroglobulinemia

Cancer Therapy Advisor asked 3 experts to weigh in on recommended treatment modalities for patients with Waldenström macroglobulinemia.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Latest Features

Preexisting Immunity to CRISPR-Cas9: A Problem for Gene Editing in Cancer?

Preexisting Immunity to CRISPR-Cas9: A Problem for Gene Editing in Cancer?

Evidence is building to show that most people have preexisting immunity to CRISPR-based therapies. In cancer, however, it's unclear how much that matters.

Cancer Recurrence: Tackling a Valid Survivor Fear

Cancer Recurrence: Tackling a Valid Survivor Fear

Researchers are learning that roughly half of survivors live with a moderate to high degree of fear of recurrence, and teaching techniques to better cope with uncertainty is one way to help.

Lower-Dose, Shorter-Duration Chemotherapy Regimens: Is This a Trend?

Lower-Dose, Shorter-Duration Chemotherapy Regimens: Is This a Trend?

Lower doses and shorter treatment regimens have the potential to reduce both physical and financial toxicity for patients.

CD19 CAR T-Cell Therapies: "Expect an Evolution"

CD19 CAR T-Cell Therapies: "Expect an Evolution"

"CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses," according to Dr Michel Sadelin.

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs